1990~2010年间心房颤动(AF)的总负荷、发病率、罹患率及与其相关联的死亡率逐渐增高。传统的做法是AF的发展中包含着:药物学新途径,控制心律失常,研制新的口服抗凝剂以预防脑卒中。但抗心律失常药物针对的不是AF的基本机制,不能很好耐受、有不良副作用甚至致命。常用的口服抗凝剂也是如此,apixabam、dabigatran、exdoxaban、rivaroxaban等都是按危 The total load, morbidity, attack rate and associated mortality of atrial fibrillation (AF) increased gradually from 1990 to 2010. The traditional approach is the development of AF contains: a new drug pharmacology, control of arrhythmias, the development of new oral anticoagulants to prevent stroke. However, anti-arrhythmic drugs are not targeted at the basic mechanism of AF, not well tolerated, with adverse side effects and even fatal. Commonly used oral anticoagulants as well, apixabam, dabigatran, exdoxaban, rivaroxaban, etc. are all according to the crisis